terazosin has been researched along with Heart Failure in 6 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the hemodynamic effects of a new alpha-1 blocker, terazosin, in congestive heart failure, 10 patients with this condition underwent hemodynamic testing at rest." | 7.68 | Hemodynamic effects of terazosin in congestive heart failure. ( Liu, Z; Lu, Z; Wang, D; Yang, D; Zhu, J, 1993) |
| "To determine the hemodynamic effects of a new alpha 1 blocker, terazosin, in congestive heart failure, six patients with this condition underwent hemodynamic testing (at rest and during exercise) before and after dosing." | 7.67 | The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure. ( Huss, P; Leier, CV; Parrish, D; Patterson, SE; Unverferth, DV, 1986) |
| "Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist." | 6.37 | Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension. ( Eisen, G; Frishman, WH; Lapsker, J, 1988) |
| "Ten patients with congestive heart failure (class III and IV) underwent hemodynamic evaluation before and after a 5-mg oral dose of terazosin." | 5.28 | Rest and exercise cardiovascular effects of terazosin in congestive heart failure. ( Boudoulas, H; Leier, CV; Magorien, RD; Sinnathamby, S; Unverferth, DV, 1990) |
| "To determine the hemodynamic effects of a new alpha-1 blocker, terazosin, in congestive heart failure, 10 patients with this condition underwent hemodynamic testing at rest." | 3.68 | Hemodynamic effects of terazosin in congestive heart failure. ( Liu, Z; Lu, Z; Wang, D; Yang, D; Zhu, J, 1993) |
| "To investigate intrarenal hemodynamics and effects of alpha 1-adrenergic blockade on glomerular functions in congestive heart failure (CHF), micropuncture studies were performed before and after intravenous injection of terazosin (1 microgram/100 g body wt iv) in eight myocardial infarction (MI) and in nine sham-operated rats after intraperitoneal injection of Inactin (70 mg/kg)." | 3.68 | Effects of alpha 1-adrenergic blockade on intrarenal hemodynamics in heart failure rats. ( Frohlich, ED; Nishikimi, T; Uchino, K, 1992) |
| "The pharmacokinetics of terazosin have been assessed in human volunteers, hypertensive patients, a limited number of elderly volunteers, and a small number of patients with congestive heart failure." | 3.67 | Pharmacokinetics of terazosin. ( Sonders, RC, 1986) |
| "To determine the hemodynamic effects of a new alpha 1 blocker, terazosin, in congestive heart failure, six patients with this condition underwent hemodynamic testing (at rest and during exercise) before and after dosing." | 3.67 | The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure. ( Huss, P; Leier, CV; Parrish, D; Patterson, SE; Unverferth, DV, 1986) |
| "Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist." | 2.37 | Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension. ( Eisen, G; Frishman, WH; Lapsker, J, 1988) |
| "Ten patients with congestive heart failure (class III and IV) underwent hemodynamic evaluation before and after a 5-mg oral dose of terazosin." | 1.28 | Rest and exercise cardiovascular effects of terazosin in congestive heart failure. ( Boudoulas, H; Leier, CV; Magorien, RD; Sinnathamby, S; Unverferth, DV, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, J | 1 |
| Wang, D | 1 |
| Lu, Z | 1 |
| Liu, Z | 1 |
| Yang, D | 1 |
| Nishikimi, T | 1 |
| Uchino, K | 1 |
| Frohlich, ED | 1 |
| Magorien, RD | 1 |
| Sinnathamby, S | 1 |
| Leier, CV | 2 |
| Boudoulas, H | 1 |
| Unverferth, DV | 2 |
| Sonders, RC | 1 |
| Patterson, SE | 1 |
| Huss, P | 1 |
| Parrish, D | 1 |
| Frishman, WH | 1 |
| Eisen, G | 1 |
| Lapsker, J | 1 |
1 review available for terazosin and Heart Failure
| Article | Year |
|---|---|
Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Heart Failure; Humans; Hypertension; Prazosin | 1988 |
5 other studies available for terazosin and Heart Failure
| Article | Year |
|---|---|
Hemodynamic effects of terazosin in congestive heart failure.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Female; Heart Failure; Hemodynamics; Humans; | 1993 |
Effects of alpha 1-adrenergic blockade on intrarenal hemodynamics in heart failure rats.
Topics: Adrenergic alpha-Antagonists; Animals; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Kidn | 1992 |
Rest and exercise cardiovascular effects of terazosin in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Coronary Circulation; Exercise; Female; Heart Failure; Hemodynamics; H | 1990 |
Pharmacokinetics of terazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Blood Proteins; Chemical Phenomen | 1986 |
The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Dose-Response Relationship, Drug; Exercise Test; Female; | 1986 |